Merck KGaA to Acquire Bio-Techne for $11.3 Billion

German pharmaceutical and chemical company Merck KGaA has announced its acquisition of American biotechnology firm Bio-Techne in a deal valued at approximately $11.3 billion. This strategic move aims to strengthen Merck's presence in the life sciences and biotechnology sectors. Under the agreement, Merck will make a cash offer for Bio-Techne's shares. Bio-Techne is known for developing innovative biological reagents and tools used in areas such as cell and gene therapy, diagnostics, and drug discovery. Merck KGaA's CEO stated that this acquisition is a key part of the company's growth strategy and that Bio-Techne's portfolio will create synergies with its own business segments. The transaction is expected to close in the first half of 2025, pending regulatory approvals. This acquisition solidifies Merck's position in the biotechnology sector while offering potential to expand Bio-Techne's R&D capabilities and customer base. Financial analysts view the deal as potentially value-creative for both companies. This is not investment advice.